Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Rodent Animal Models for Drug Discovery
share announcement

Rodent Animal Models for Drug Discovery

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 30 August 2024 | Viewed by 2798

Special Issue Editors

Dr. Yuebang Yin

E-Mail Website
Guest Editor
Hunan Provincial Key Laboratory of Animal Nutritional Physiology and Metabolic Process, Institute of Subtropical Agriculture, Chinese Academy of Sciences, Changsha 410125, China
Interests: rodent; animal model; mouse; rat; drug discovery; organoid; 3D model
Dr. Peng Wang

E-Mail Website
Guest Editor
Ningxia Key Laboratory of Cerebrocranial Diseases, Ningxia Medical University, Yinchuan 750004, China
Interests: neurosciences; animal model; rodent; cell model; drug discovery; medical study

Special Issue Information

Dear Colleagues,

Laboratory rodents, particularly the mouse and rat, are the preferred and most frequently used animal models in biomedical research. These models can provide results that allow us to deduce knowledge to study a particular disease state in humans. Rodents have been regarded as a reliable research species mainly due to their small size, short life cycle, reproductive affluence, known genetic background, as well as relative ease of procurement, handling, and housing. With the development of biotechnologies, genetic manipulations further strengthen the predominant utilization of rodents. These manipulations have allowed the researcher to study rat or mice genetically suited specifically to the human disease model of their interests. Thus, rodent animal models play an essential role in drug discovery and medical studies.

Drug discovery is the process through which potential new medicines are identified. The drug discovery process is invariably a lengthy and expensive process in the pharmaceutical industry, which starts with the identification and validation of the putative molecular/cellular drug target, followed by generally lengthy preclinical and clinical investigations, with the process ending in a series of regulatory approvals. Animal models for drug discovery and development have played an important role in the characterization of the pathophysiology of diseases and associated mechanisms of injury, drug target identification, and evaluation of novel therapeutic agents for toxicity/safety, pharmacokinetics, pharmacodynamics, and efficacy. The use of animal models is vitally important in terms of developing clinical predictions of the expected results in humans.

In this Special Issue, we aim to draw together research from experts in the field that highlight applications of rodent animals in drug discovery, covering the utilization of rodent animals, ex vivo tissue in medical research, and identify future directions that will lead to the perfect utilization of rodent animals in drug discovery.

Dr. Yuebang Yin
Dr. Peng Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal model
  • rodent
  • mouse
  • rat
  • drug discovery

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3506 KiB  
Article
Metformin Hydrochloride Significantly Inhibits Rotavirus Infection in Caco2 Cell Line, Intestinal Organoids, and Mice
by Rui Zhang, Cui Feng, Dandan Luo, Ruibo Zhao, Perumal Ramesh Kannan, Yuebang Yin, Muhammad Zubair Iqbal, Yeting Hu and Xiangdong Kong
Pharmaceuticals 2023, 16(9), 1279; https://doi.org/10.3390/ph16091279 - 11 Sep 2023
Cited by 3 | Viewed by 1282
Abstract
Rotavirus is one of the main pathogens that causes severe diarrhea in children under the age of 5, primarily infecting the enterocytes of the small intestine. Currently, there are no specific drugs available for oral rehydration and antiviral therapy targeting rotavirus. However, metformin [...] Read more.
Rotavirus is one of the main pathogens that causes severe diarrhea in children under the age of 5, primarily infecting the enterocytes of the small intestine. Currently, there are no specific drugs available for oral rehydration and antiviral therapy targeting rotavirus. However, metformin hydrochloride, a drug known for its antiviral properties, shows promise as it accumulates in the small intestine and modulates the intestinal microbiota. Therefore, we formulated a hypothesis that metformin hydrochloride could inhibit rotavirus replication in the intestine. To validate the anti-rotavirus effect of metformin hydrochloride, we conducted infection experiments using different models, ranging from in vitro cells and organoids to small intestines in vivo. The findings indicate that a concentration of 0.5 mM metformin hydrochloride significantly inhibits the expression of rotavirus mRNA and protein in Caco-2 cells, small intestinal organoids, and suckling mice models. Rotavirus infections lead to noticeable pathological changes, but treatment with metformin has been observed to mitigate the lesions caused by rotavirus infection in the treated group. Our study establishes that metformin hydrochloride can inhibit rotavirus replication, while also affirming the reliability of organoids as a virus model for in vitro research. Full article
(This article belongs to the Special Issue Rodent Animal Models for Drug Discovery)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

34 pages, 11241 KiB  
Review
Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents
by Magdalena Jasińska-Stroschein
Pharmaceuticals 2023, 16(10), 1449; https://doi.org/10.3390/ph16101449 - 12 Oct 2023
Viewed by 1188
Abstract
Background: While the prevalence of heart failure with preserved ejection fraction (HFpEF) has increased over the last two decades, there still remains a lack of effective treatment. A key therapeutic challenge is posed by the absence of animal models that accurately replicate the [...] Read more.
Background: While the prevalence of heart failure with preserved ejection fraction (HFpEF) has increased over the last two decades, there still remains a lack of effective treatment. A key therapeutic challenge is posed by the absence of animal models that accurately replicate the complexities of HFpEF. The present review summarizes the effects of a wide spectrum of therapeutic agents on HF. Methods: Two online databases were searched for studies; in total, 194 experimental protocols were analyzed following the PRISMA protocol. Results: A diverse range of models has been proposed for studying therapeutic interventions for HFpEF, with most being based on pressure overload and systemic hypertension. They have been used to evaluate more than 150 different substances including ARNIs, ARBs, HMGR inhibitors, SGLT-2 inhibitors and incretins. Existing preclinical studies have primarily focused on LV diastolic performance, and this has been significantly improved by a wide spectrum of candidate therapeutic agents. Few experiments have investigated the normalization of pulmonary congestion, exercise capacity, animal mortality, or certain molecular hallmarks of heart disease. Conclusions: The development of comprehensive preclinical HFpEF models, with multi-organ system phenotyping and physiologic stress-based functional testing, is needed for more successful translation of preclinical research to clinical trials. Full article
(This article belongs to the Special Issue Rodent Animal Models for Drug Discovery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop